This study demonstrated that adjunctive evolocumab therapy significantly improved clinical outcomes and inhibited the elevation of the plasma IL-6 compared to atorvastatin monotherapy in AIS patients, whereas peripheral blood T lymphocyte subsets did not change in this trial. The gene discussed is IL6; the disease is androgen insensitivity syndrome.